Table 3.
Association analyses between variants and therapeutic effect of neoadjuvant chemotherapy in the replication stage.
| SNPs | HT vs. HW | HV vs. HW | Additive model | Dominant model | Recessive model | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI)a | P | OR (95% CI)a | P | OR (95% CI)a | P | OR (95% CI)a | P | OR (95% CI)a | P | |
| rs6484711 | 0.63 (0.28–1.39) | 0.253 | 0.35 (0.13–0.91) | 0.032 | 0.59 (0.37–0.96) | 0.033 | 0.53 (0.25–1.11) | 0.094 | 0.46 (0.20–1.05) | 0.065 |
| rs184301136 | 1.81 (0.90–3.65) | 0.095 | – | – | 1.81 (0.90–3.65) | 0.095 | 1.82 (0.91–3.66) | 0.092 | – | – |
HW, wild type homozygote; HT, heterozygote; HV, variant homozygote; OR, odds ratio; 95% CI, 95% confidence interval. The significant results were in bold.
a
Data were calculated by unconditional logistic regression model after adjusting for age, menopause status, lymph node metastasis, myelosuppression, gastrointestinal side effects.